Abstract: Poster Presentations |

A Comparison of Patient Perceived Improvement in Symptoms After Initiating Therapy with Either Advair Diskus (fluticasone propionate/salmeterol) 250/50 or Ipratropium/Albuterol FREE TO VIEW

Katharine Knobil, MD*; Kunal Merchant, PhD; Chris Kalberg, PhD; Amanda Emmett, MS; Michael Cicale, MD
Author and Funding Information

GlaxoSmithKline, Research Triangle Park, NC


Chest. 2004;126(4_MeetingAbstracts):806S-b-807S. doi:10.1378/chest.126.4_MeetingAbstracts.806S-b
Text Size: A A A
Published online


PURPOSE:  This retrospective analysis compares the onset of relief from COPD symptoms after initiating therapy with either Advair Diskus 250/50 BID or ipratropium/albuterol 36/206mcg QID via MDI (IB/ALB).

METHODS:  Patient-recorded diary data was evaluated from two randomized, double-blind, parallel group trials of COPD patients (n=726) randomized to FSC or IB/ALB for 8 weeks. Patients were ≥40 years of age with symptomatic COPD, had a FEV1/FVC <0.7 and a FEV1 40 to 70% of predicted normal (baseline mean=43%), and did not use inhaled or oral corticosteriods for at least 30 days prior to randomization. Patients recorded a daily diary with AM peak expiratory flow (PEF), nighttime awakenings requiring albuterol, and day and sleep symptom scores using a Visual Analogue Scale (VAS). Data from treatment day 1 to day 7 were compared between treatment groups to evaluate the onset of COPD symptom relief.

RESULTS:  Overall, symptom improvement was noted in both treatment groups, however, patients treated with Advair 250/50 consistently indicated early and significantly greater improvements in symptoms compared with IB/ALB. These patients perceived improvements following the significant increase in mean AM PEF starting at day 1 for Advair 250/50 (17.7 L/min) compared with IB/ALB (5.4 L/min) (p<0.001). The improvements seen early were sustained throughout the 8-week study period.

CONCLUSION:  Patients perceive significantly greater improvement in COPD symptoms as early as day 1 after initiating treatment with Advair 250/50 BID compared to IB/ALB 36/206mcg QID.

CLINICAL IMPLICATIONS:  Use of an inhaled corticosteroid and long acting beta-agonist together provides patient perceived improvement in COPD symptoms within one day of starting treatment. This may encourage patient compliance and therefore lead to improved efficacy.

Changes in FEV1 Responses From Day 1 to Week 8

FSC (n=303)IB/ALB (N=299)Peak FEV1 change from baseline, mL51.5 (18.3%)-17.7 (-5.4%)FEV1AUC0–6, L-hr0.33 (22.7%)-0.22 (-14.2%)FEV1AUC0–4, L-hr0.25 (24.6%)-0.11 (-10.9%)FEV1AUC0–2, L-hr0.15 (26.7%)-0.03 (-5.9%)

DISCLOSURE:  K. Knobil, None.

Wednesday, October 27, 2004

12:30 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
Treatment of acute exacerbation of asthma.
Finnish Medical Society Duodecim | 1/25/2008
Long-term management of asthma.
Finnish Medical Society Duodecim | 1/11/2008
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543